The positive expression rate of FXYD6 protein in CC tissue was notably higher than that in distal bile duct tissue (69 vs. 33.3%; P=0.002), indicating that FXYD6 may be a new potential biomarker and therapeutic target for CC. Here, FXYD6 is linked to cholangiocarcinoma.